AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02866097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth inventory management
Description: Improved stock management of iCCM commodities using the DHIS2 mHealth platform
Study NCT02866097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive supervision
Description: Strengthening of supportive supervision using DHIS2
Study NCT02866097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ICCM current standard of care
Description: ICCM implementation as per current practice without mHealth interventions
Study NCT03192657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: The first administration should be within 8 weeks after disease onset.
Study NCT03192657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin Inhibitors
Description: Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
Study NCT03192657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin Inhibitors
Description: Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
Study NCT03192657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Dosage of steroid can be adjusted according to personal experience of the researcher.
Study NCT03192657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Dosage of steroid can be adjusted according to personal experience of the researcher.
Study NCT03986281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omron Wearable Device
Description: Omron wearable device compared to arterial line readings
Study NCT03986281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arterial Line
Description: Omron wearable device compared to arterial line readings
Study NCT04619251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: BI 1323495
Study NCT03148613 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bedfont - Micro+™ Smokerlyzer®
Description: Bedfont - Micro+™ Smokerlyzer® : Predicate Device to measure carbon monoxide levels in one's breath.
Study NCT04347863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group swallowing disorder diet preparation program
Description: This program included food properties, select food, type of cooking, using thickener and tasting
Study NCT02894671 — intervention group
Intervention type: OTHER
Intervention: blood exams
Description: in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
Study NCT03393234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Interoperative radiation by INTRABEAM using low energy X-ray
Description: Intrabeam is a mobile Platform for Intraoperative Radiotherapy (IORT) produced by the ZEISS company in Germany.Interoperative radiation by INTRABEAM using low energy X-ray.The Intrabeam PRS appears to be a safe technique for delivering IORT in rectal cancer patients.
Study NCT03531671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binocular-OCT
Description: Binocular Optical Coherence Tomographer used to assess both eyes in the same session without the need for a trained assistant.
Study NCT00377793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Study NCT00377793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01141712 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous transplant
Description: Participants will receive the BEAM conditioning regimen followed by autologous HCT.
Study NCT01141712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BCNU
Description: Participants will receive BCNU 300 mg/m\^2 Day -6
Study NCT01141712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: Participants will receive Etoposide 100 mg/m\^2 BID Days -5 to -2
Study NCT01141712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Participants will receive Cytarabine 100 mg/m\^2 BID Days -5 to -2
Study NCT01141712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Participants will receive Melphalan 140 mg/m\^2 Day -1
Study NCT03634085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDM-2 in Bottle (50 mg - 3600 mg); oral suspension
Description: BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine, Arm A
Description: 200 mg b.i.d. x 7 days every 3-4 weeks
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine, Arm B
Description: 300 mg b.i.d. x 7 days every 3 - 4 weeks
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine, Arm C
Description: 400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
Study NCT04619251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04619251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study NCT01852253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2% chlorhexidine
Study NCT01852253 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 0.12% chlorhexidine
Study NCT02191410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Positive Pressure Ventilation
Description: TV 2 mL kg-1 PBW, I:E ratio > 0.3, RR 60 breaths min-1 and a FGF of \< 2 L min-1, using a second identical ventilator with low compliant internal circuit
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine, Arm D
Description: 200 mg b.i.d. x 7 consecutive days every 4 weeks
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine, Arm E
Description: 300 mg q.d. x 7 consecutive days every 4 weeks
Study NCT02191410 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: CPAP of 2 cm H2O
Study NCT01624103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper limb surgery
Description: Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine, Arm F
Description: 300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine, Arm G
Description: 200 mg b.i.d. x 7 consecutive days every 4 weeks
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine, Arm H
Description: 300 mg q.d. x 7 consecutive days every 4 weeks
Study NCT01624103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper limb surgery
Description: Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
Study NCT00590187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine, Arm I
Description: 100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
Study NCT01946139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: comparison of screening methods
Description: Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
Study NCT01946139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01946139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01946139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00296816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin®)
Description: 15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
Study NCT00296816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Description: 75 mg/m\^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
Study NCT00296816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (Eloxatin®)
Description: 85 mg/m\^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
Study NCT00348439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: 27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
Study NCT00348439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
Study NCT01664910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic BM transplant
Study NCT01664910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSC or BM transplant
Study NCT01664910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT01664910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT04662177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management.
Study NCT01664910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT03895905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: colposcopy and colposcopic biopsy
Description: high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.
Study NCT04537416 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01664910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT04310280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Half of the wound surface is injected daily with topical glargine insulin
Study NCT04310280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Half of the wound surface is injected daily with topical saline solution
Study NCT03218397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerate PhenoTest™ BC Kit
Description: Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
Study NCT03218397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Culture and AST
Description: Standard culture and antimicrobial susceptibility testing (AST)
Study NCT01453543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep transverse friction massage
Description: For the application of the deep transverse friction massage, the participants were positioned supine with the ankle in 90 ° of dorsiflexion, in order to bring some tension on the tendon. The treating clinician stabilized the subject's foot with one hand while applying the DTF with the other hand. The deep friction massage is a pinching technique with thumb and index finger, reinforced by the middle finger.
Study NCT01664910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT01664910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT01664910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01664910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT02104453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: airway maneuver
Description: Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.~Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)
Study NCT03795259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: After induction, rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%.
Study NCT03795259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given intravenously.
Study NCT00943111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate
Description: Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (\<) 5 nanogram per milliliter \[ng/mL\] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.~Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6.
Study NCT00943111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiglucerase
Description: PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.~LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was \<5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was >=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively.
Study NCT04072068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
Study NCT03629743 — intervention group
Intervention type: DEVICE
Intervention: EEG
Description: EEG will be collected with Brain Product's VAMP-16 channel EEG Monitor using the accompanying software. (Website with further specifications and product details: https://www.brainproducts.com/productdetails.php?id=15)
Study NCT00854230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone dose 25-100mg
Study NCT00854230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone dose 25-100mg
Study NCT02354274 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Escalated: Inhomogeneous dose plan
Study NCT02354274 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard: Homogeneous dose plan
Study NCT02183857 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Study NCT02183857 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Landmark
Study NCT04113317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (Filgrastim)
Description: Contains 0,59 mg of acetate, 0,04 mg of polysorbate 80, 0,035 mg of sodium, 50 mg of sorbitol
Study NCT02036047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)
Study NCT03629743 — intervention group
Intervention type: DEVICE
Intervention: ECOG
Description: ECOG will be collected with Nihon Kohden acquisition System and accompanying software and depth electrodes.
Study NCT01796548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutinin Extended-Release
Description: Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
Study NCT03229590 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical dislocation
Description: Reduction of slipped epiphysis by surgical dislocation
Study NCT02036047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular polypectomy snare (Snare Master, SD-210U-10)
Study NCT04249856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic Spectral Imaging (DYSIS)
Description: Women who have a colposcopy exam performed at Randers Regional Hospital were examined by Dynamic Spectral Imaging colposcopy (DYSIS)
Study NCT00152893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chromium nicotinate
Study NCT00152893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01992952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
Study NCT01992952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
Study NCT04592588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Toolbox
Description: COMET is an online unguided self-help intervention that lasts approximately 45-60 minutes.
Study NCT01992952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
Study NCT04592588 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wait-list control
Description: Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
Study NCT01992952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: 2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
Study NCT03667157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: every week IVMP therapy
Description: 12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
Study NCT03667157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: very high doses IVMP therapy
Description: 3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
Study NCT00314743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study NCT00314743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Study NCT00314743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone